longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

512290

512290
----

LongbridgeAI

Shenzhen New Industries Biomedical Engineering : Revenue and profit rose double digits, with strong reagent growth and overseas momentum

Quartr
Aug 13, 2026 at 04:03 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Revenue rose 10.78% and net profit grew 12.53% year-over-year, driven by strong reagent sales and overseas expansion. Gross margin improved to 71.09%, with robust cash flow and continued investment in R&D and automation.Original document: Shenzhen New Industries Biomedical Engineering Co. Ltd. Class A [300832] Interim report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Revenue rose 10.78% and net profit grew 12.53% year-over-year, driven by strong reagent sales and overseas expansion. Gross margin improved to 71.09%, with robust cash flow and continued investment in R&D and automation.

Original document: Shenzhen New Industries Biomedical Engineering Co. Ltd. Class A [300832] Interim report — Aug. 13 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Login to unlock482characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Snibe

Snibe

300832.SZ

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--